News ReleaseView printer-friendly version
Quidel Announces U.S. Market Launch of Urinalysis Product
SAN DIEGO, Aug. 16 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today the market introduction of its new QuickVue(R) UrinChek(TM) 10+ SG urine test strips in the United States. This product, currently marketed in Europe under the Rapignost(R) brand name, offers healthcare providers a quick, simple-to-use diagnostic test to assist a physician in assessing the health of a patient. Designed specifically to simplify visual test result reading, the QuickVue UrinChek test strips chemically analyze a specimen to detect the presence of ten important health markers that assist in the diagnosis of diabetes, liver and kidney disease, urinary tract infection and other ailments.
"The U.S. launch of our urinalysis test strip product provides an entry into a substantial diagnostic market and expands the popular QuickVue line of high-quality, easy-to-use, point-of-care diagnostic products. This technology offers several improvements over other products on the market today," said Lin Tanner, Senior Vice President, Global Commercial Operations. "We believe the UrinChek product will be well received by healthcare professionals and expect it to begin contributing to profits later this year."
The QuickVue UrinChek 10+ SG tests for or measures the level of the following compounds in a urine specimen: bilirubin, urobilinogen, ketones, glucose, protein, blood, pH, nitrite, leukocytes, specific gravity and ascorbic acid. An important innovation in the QuickVue urinalysis strips is the test for the presence of ascorbic acid (vitamin C) in the patient's specimen. Scientific evidence overwhelmingly indicates vitamin C inhibits color development on urine test strips for glucose, blood, nitrite and bilirubin. With the QuickVue test strips, healthcare providers can detect the presence of ascorbic acid in urine and are alerted to the possibility of a false negative result. "We believe this additional test is particularly important with the increasing popularity of vitamin C supplements," stated Stephen C. Biby, Marketing Manager.
Quidel is a market leader in point-of-care, rapid diagnostics providing simple, accurate and cost-effective tests to physicians and/or consumers. QDEL's Test and Treat products are easy to use and provide results in minutes, facilitating rapid treatment, improved health outcomes, reduced costs, and increased patient satisfaction. Its core products address issues relating to a woman's health throughout her life including reproductive status, pregnancy management and osteoporosis. The company also provides diagnostic products for all family members for common health problems and infectious diseases, including influenza A and B, strep throat, H. pylori infection (peptic ulcers), chlamydia and mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories, pharmacies, and wellness screening centers. Quidel also manufactures a line of products sold to consumers through organizations that provide store branded products.
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results such that actual results and performance may differ materially. Quidel's financial condition and operating results may also be materially and adversely affected by a number of factors, including, without limitation, the company's ability to successfully introduce new products and the speed of market acceptance for its products, manufacturing and deliver capabilities, adverse changes in competitive and economic conditions, or regulatory actions affecting the company, product or industry. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.
Charles J. Cashion, Chief Financial Officer,858-552-7962,
or Stephen C. Biby, Marketing Manager,858-552-7933, both of Quidel Corporation